ABSTRACT
INTRODUCTION: Lung cancer is the most frequently diagnosed type of cancer and the main cause of death from malignant neoplasms worldwide. One of the most recent discoveries in the context of non-small cell lung cancer (NSCLC) was the mutation of the anaplastic lymphoma kinase receptor (ALK). This genetic alteration is found in approximately 2-5% of NSCLC patients, and crizotinib was the first targeted therapy discovered for its first-line treatment. OBJECTIVE: To conduct a systematic review and meta-analysis to estimate the magnitude of the overall survival (OS) and progression-free survival (PFS) from using crizotinib as treatment compared to traditional chemotherapy to guide future decision making. METHODS: PRISMA and Cochrane recommendations were followed using the findings based on studies published in the main international electronic databases. Selection criteria included the following: randomized clinical trials (RCT) or cohort studies that had assessed the efficacy and effectiveness of crizotinib as monotherapy in patients with NSCLC with ALK fusions. RESULTS: From 2504 publications identified in the literature, only eight publications referring to seven studies met the selection criteria, with high heterogeneity identified between the studies. Overall, there was a significant gain in PFS (HR 0.38; 95% CI 0.30-0.49; p < 0.00001); however, there was no significant gain in OS (HR 0.68; 95% CI 0.43-1.08; p = 0.10). CONCLUSION: The study highlighted and confirmed that treatment with crizotinib led to clinical improvement in PFS among patients with advanced NSCLC with ALK fusion, as previously reported. However, there was no increase in overall survival in patients with NSCLC with genetic alterations of ALK. This must be considered when reviewing and funding treatments for NSCLC patients with this mutation.
ABSTRACT
The authors wish to make a change to their published paper [...].
ABSTRACT
This work reports on the development of bending actuators based on poly(l-lactic acid) (PLLA)/ionic liquid (IL) blends, through the incorporation of 40% wt. of the 1-ethyl-methylimidazolium bis(trifluoromethylsulfonyl)imide ([Emim][TFSI]) IL. The films, obtained by solvent casting at room temperature and 50 °C, were subjected to several post-thermal treatments at 70, 90, 120 and 140 °C, in order to modify the crystallinity of the films. The influence of the drying temperature and of [Emim][TFSI] blending on the morphological, structural, mechanical and electrical properties of the composite materials were studied. The IL induced the formation of a porous surface independently of the processing conditions. Moreover, the [Emim][TFSI] dopant and the post-thermal treatments at 70 °C promoted an increase of the degree of crystallinity of the samples. No significant changes were observed in the degree of crystallinity and Young Modulus for samples with thermal treatment between 70 and 140 °C. The viability of the developed high ionic conductive blends for applications as soft actuators was evaluated. A maximum displacement of 1.7 mm was achieved with the PLLA/[Emim][TFSI] composite prepared at 50 °C and thermally treated at 140 °C, for an applied voltage of 10 Vpp, at a frequency of 100 mHz. This work highlights interesting avenues for the use of PLLA in the field of actuators.
